Nordic Alzheimer Symposium
Thursday 28th January 2027
| Time | Content | Speaker |
|---|---|---|
| 12.00-13.00 | Lunch | |
| 13.00-13.10 | Welcome | BioArctic |
| Chapter 1 ABC of AD – where are we now? | Chair: Anne Koivisto (FI) | |
| 13.10-13.30 | Decoding Alzheimer’s Disease Heterogeneity | Laura Parkkinen (UK) |
| 13.30-13.50 | Imaging in AD moving into the future | Eric Westman (SE) |
| 13.50-14.10 | Panel discussion/Q&A | Anne Koivisto, Laura Parkkinen & Eric Westman |
| 14.10-14.40 | Coffee break | |
| Chapter 2 Early diagnosis and biomarkers in AD | Chair: Silke Kern (SE) | |
| 14.40-15.00 | Status on new biomarkers in AD and dementia diseases | Henrik Zetterberg (SE) |
| 15.00-15.20 | Practical implementation of AD biomarkers in clinical practice – lessons learned | Tormod Fladby (NO) |
| 15.20-15.40 | Panel discussion country perspectives incl. primary care aspects /Q&A | Silke Kern, Henrik Zetterberg & Tormod Fladby |
| 15.40-16.10 | Coffee break 2 | |
| Chapter 3 Decision support tools and management of AD | Chair: Dag Årsland (NO) | |
| 16.10-16.30 | Supporting primary care in AD management through a multidisciplinary approach | Anna von Nandelstadh (FI) |
| 16.30-16.50 | Support tool projects ongoing in the Nordics (IHI) | Hanneke Rhodius-Meester (NO) |
| 16.50-17.10 | Panel discussion – how to include in the future in Nordic healthcare setting? | Dag Årsland, Anna von Nandelstadh & Hanneke Rhodius-Meester |
| 17.10-17.20 | Wrap up day 1 | Organizers |
Friday 29th January 2027
| Time | Content | Speaker |
|---|---|---|
| 09.00-09.10 | Opening of day 2 | BioArctic |
| Chapter 4 Treatment of AD in clinical practice | Chair: Dag Årsland (NO) | |
| 09.10-09.30 | Appropriate use recommendations for DMT* in AD | Kristian Steen Frederiksen (DK) |
| 09.30-09.50 | Updates on DMTs* and new AD treatments | Sebastian Palmqvist (SE) |
| 09.50-10.10 | Panel discussion/Q&A | Dag Årsland, Kristian Steen Frederiksen & Sebastian Palmqvist |
| 10.10-10.40 | Coffee break | |
| Chapter 5 Experience and use of DMTs* in clinical practice | Chair: Kristian | |
| 10.40-11.00 | Clinical experience with DMTs* from Austria | Elisabeth Stögmann (AT) |
| 11.00-11.20 | Implementation of and experiences with anti-amyloid immunotherapies in a private clinic in Finland | Minna Raivio (FI) |
| 11.20-11.40 | Panel discussion/Q&A | Kristian Steen Frederiksen, Elisabeth Stögmann & Minna Raivio |
| 11.40-12.00 | Wrap up and closing of symposium | Steering Committee & organizers |
| 12.00-13.00 | Lunch and departure |
*Disease Modifying Therapies
